Pacific Biosciences Acquires Circulomics – A Leading High Molecular Weight DNA Extraction Company
August 03 2021 - 8:00AM
Pacific Biosciences of California, Inc. (Nasdaq: PACB) (“Pacific
Biosciences” or “PacBio”), a leading provider of high-quality,
long-read sequencing platforms, announced today that it acquired
Circulomics Inc. (“Circulomics”), a Maryland-based biotechnology
company focused on delivering highly differentiated sample prep
products that enable genomic workflows. Scientists recognize
Circulomics as a leader in extracting high quality, high molecular
weight (HMW) DNA from almost any sample type. These products are
commonly used for long read applications across a diverse set of
markets including, human biomedical research, plant and animal
sciences and microbiology.
“One of our core strategies is to improve the front end of our
sequencing workflows. The Nanobind technology that Circulomics has
created is already proven in the market and will accelerate our
efforts to make sample extraction and library preparation easier
for our customers,” said Christian Henry, CEO and President at
PacBio. “By adding the team to PacBio we will be able to deeply
integrate their technology into our workflows which will improve
our entire long-read sequencing workflow.”
“High quality, long-read sequencing begins with high quality,
long DNA. The talented Circulomics team will extend our
capabilities in extraction and sample prep and will help us deliver
a much easier path toward an end-to-end automated workflow,” said
Dr. Catherine Ball, Senior Vice President of Research at PacBio.
“This team and their elegant technology have the potential for
impact across the entire genomics workflow from front-end sample
preparation to multiplex assays, library prep, and
beyond.”
HMW DNA ranges from 50 to 300+ kilobases in length – an ideal
size for long-read sequencing with PacBio or other long-read
sequencing platforms. Circulomics’ Nanobind magnetic disks
protect DNA from shearing to generate long reads across a broad
range of sample types. Their products can be used to sequence a
wide range of samples from cells, bacteria, and fungi, to plants,
insects, fish, mammals, and reptiles.
“We built a company of scientists who bend over backwards to
help our customers generate beautiful sequencing data. Our goal has
always been to build products that enable customers to focus on
science rather than stress over sample prep. Through collaborations
with PacBio, we know we share the same values and obsession with
customer success,” said Dr. Kelvin Liu, Founder and CEO at
Circulomics. “Joining PacBio is such a natural fit. We’re excited
to work together to push the boundaries of genomics.”
All customers will continue to receive Circulomics product and
support.
The financial terms of the deal were not disclosed, and the pro
forma financial impact of the acquisition is not expected to be
material in 2021.
For more information, please visit www.pacb.com/circulomics.
The Company will discuss the acquisition of Circulomics and its
financial results, which remain largely consistent with the
Company’s preliminary results shared on July 20, 2021, for the
fiscal second quarter on its quarterly conference call after market
close today. The call will be webcast and may be accessed at the
Company’s website at: https://investor.pacificbiosciences.com/.
Date: August 3, 2021
Time: 4:30pm ET
Listen via Internet:
https://investor.pacificbiosciences.com/
Toll-free: 888.366.7247
International: 707.287.9330
Conference ID: 6914707
Replay: https://investor.pacificbiosciences.com
These announcements are available on the Pacific Biosciences
Investor Relations website at ir.pacb.com.
About Pacific BiosciencesPacific Biosciences of
California, Inc. (NASDAQ: PACB) is empowering life scientists with
highly accurate long-read sequencing. The company’s innovative
instruments are based on Single Molecule, Real-Time (SMRT®)
Sequencing technology, which delivers a comprehensive view of
genomes, transcriptomes, and epigenomes, enabling access to the
full spectrum of genetic variation in any organism. Cited in
thousands of peer-reviewed publications, PacBio® sequencing systems
are in use by scientists around the world to drive discovery in
human biomedical research, plant and animal sciences, and
microbiology. For more information, please
visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use
Only. Not for use in diagnostic procedures.
Forward-Looking Statements This press release
may contain “forward-looking statements” within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and
the U.S. Private Securities Litigation Reform Act of 1995,
including statements relating to intentions and strategies to
improve workflows; efforts to ease sample extraction and library
preparation; ability to use Circulomics products across a wide
range of samples, and the use of such products in long read
applications across diverse markets; ideal base pair length for use
in long-read sequencing platforms, and the ability of Circulomics
products to generate DNA samples having such base pair lengths; the
continued customer support of Circulomics products; the expected
pro forma impact of the Circulomics acquisition in 2021; and, the
benefits of PacBio sequencing. Readers are cautioned not to place
undue reliance on these forward-looking statements and any such
forward-looking statements are qualified in their entirety by
reference to the following cautionary statements. All
forward-looking statements speak only as of the date of this press
release and are based on current expectations and involve a number
of assumptions, risks and uncertainties that could cause the actual
results to differ materially from such forward-looking statements.
Readers are strongly encouraged to read the full cautionary
statements contained in the Company’s filings with the Securities
and Exchange Commission, including the risks set forth in the
company’s Forms 8-K, 10-K, and 10-Q. The Company disclaims any
obligation to update or revise any forward-looking statements.
Contacts
Investors:Todd Friedman+1 (650)
521-8450ir@pacificbiosciences.com
Media:Jen Carroll+1 (858)
449-8082pr@pacificbiosciences.com
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacific Biosciences of C... (NASDAQ:PACB)
Historical Stock Chart
From Apr 2023 to Apr 2024